CD55 Mutation Diagnosis and Complement Inhibition for CHAPLE
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for accurate methods to detect and treat CD55 deficiency, hyperactivation of complement, and protein losing enteropathy (CHAPLE), a newly identified rare disease, which is often misdiagnosed due to its rare occurrence and complex pathophysiology involving genetic mutations and complement dysregulation.
Innovation Solution
A diagnostic method involving genetic testing for CD55 mutations and therapeutic compositions using complement inhibitors to treat CHAPLE symptoms by targeting CD55 deficiency and hyperactivation of complement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for rare diseases, then diagnostic time is extended (up to 5 years), but measurement precision and reliability of diagnosis deteriorate due to masked or misunderstood early stage symptoms
Solution Approach 1:
The patent applies preliminary action by implementing a targeted diagnostic approach that proactively tests for specific CD55 deficiency markers and complement activation indicators before the full clinical picture develops. This allows early detection of CHAPLE syndrome when symptoms are still subtle, preventing the 5-year diagnostic delay mentioned in the background.
Solution Approach 2:
The patent uses complement activation markers and specific antibody tests as intermediaries to detect CD55 deficiency indirectly. Rather than directly observing the rare disease manifestation, the diagnostic method measures complement system activation as a mediator that indicates underlying CD55 deficiency, enabling earlier and more accurate diagnosis.
2Reliability
If targeted therapeutic compositions are developed for CHAPLE, then treatment effectiveness improves by addressing root cause (CD55 deficiency and complement hyperactivation), but device complexity and manufacturing complexity increase due to need for specific complement inhibitors
Solution Approach 1:
The patent extracts and targets the specific pathogenic mechanism of complement hyperactivation caused by CD55 deficiency. By isolating the complement system as the specific therapeutic target and developing complement inhibitors that selectively block this pathway, the treatment addresses the root cause without requiring complex multi-target approaches.
Solution Approach 2:
The patent applies parameter changes by modifying the complement system's activation state through pharmacological intervention. Complement inhibitors alter the biochemical parameters of complement activation, reducing excessive complement consumption and stabilizing the system without requiring complex structural changes to the therapeutic agent.
3Measurement precision
If comprehensive genetic testing for CD55 mutations is performed, then diagnostic precision improves, but loss of time and resource consumption increase due to extensive testing requirements
Solution Approach 1:
The patent segments the diagnostic process into targeted molecular tests for CD55 gene mutations and complement activation markers, rather than performing exhaustive genetic screening. This segmentation allows focused detection of pathogenic variants in the CD55 gene and related complement pathway genes, achieving high diagnostic precision with reduced testing time.
Data Source
AI summary
Disclosed hereing are methods of diagnosing, and treating and/or preventing CD55-deficiency, hyperactivation of complement, angiopathic thrombosis and protein-losing enteropathy (CHAPLE). The method of diagnosing includes: providing a sample from a patient; performing an assay detecting at least one of at least one mutation in a DNA sequence of a CD55 gene, at least one mutation in a RNA sequence of a CD55 transcript, at least one mutation in a DNA sequence of a CD55 complementary-DNA (cDNA), CD55 protein, CD55 protein binding, complement deposition or combination thereof, and diagnosing the patient with CHAPLE. The method of treating and/or preventing at least one symptom of CHAPLE includes: administering an effective amount of a composition comprising at least one complement inhibitor to a subject in need thereof, wherein the composition is effective in treating or preventing at least on symptom of CHAPLE. The disclosure further relates to compositions effective at treating and/or preventing CHAPLE.